(This story was updated at 10:35 a.m. Oct. 11 with Bedrocan declining comment.)
Medical marijuana producer Bedrocan International is returning to the Canadian market through the purchase of a facility in Scarborough, Ontario.
Health Canada recently granted the Veendam, Netherlands-based company a cultivation license to grow standardized medical cannabis for Canadian patients, according to a Thursday news release.
Bedrocan declined to comment on MJBizDaily queries about the purchase price and seller’s identity.
The company said it plans to start production early next year.
Bedrocan stopped producing cannabis in Canada after a licensing arrangement with Smiths Falls, Ontario-headquartered Canopy Growth Corp. ended in 2019, according to a company spokesperson.
Bedrocan, which always planned to return to the market, sold its shares in Canopy Growth in 2016 to distance itself from the Canadian company’s strategy for large-scale production of recreational cannabis.
“We are thrilled to be coming back to Canada,” Bedrocan CEO Jaap Erkelens said in a Thursday statement.
“We look forward to serving patients in Canada and positively impacting the Canadian healthcare landscape.”
Bedrocan focuses on producing pharmaceutical-grade cannabis with consistent levels of THC and CBD.
“We have had a strictly pharmaceutical approach since our foundation in 2003,” Erkelens said.
“We use the knowledge we have acquired in more than 20 years of business to produce cannabis products that benefit patients exclusively.”
Bedrocan plans to bring several standardized cannabis products to the Canadian market, according to the release.
The products will be “distributed through a third party via the medical sales channel to registered patients.”
